Search clinical trials for: Tacrolimus (tacrolimus elimination)

Total 2305 results

Novartis Pharmaceuticals

Completed

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Liver Transplant Recipient

Belgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients (RAD)

Liver Transplantation

United States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
Kasr El Aini Hospital

Completed

Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo

Stable Vitiligo
Assiut University

Unknown

The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo

Vitiligo Vulgaris
Astellas Pharma Inc

Completed

Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Keratoconjunctivitis | Conjunctivitis

Japan
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus

Liver Transplantation

Korea, Republic of
Heleen Grootjans
Chiesi Farmaceutici S.p.A.

Recruiting

Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients (REVOLUTION)

Lung Transplant; Complications

Netherlands
The Methodist Hospital Research Institute
Veloxis Pharmaceuticals

Withdrawn

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

Acute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
Sohag University

Unknown

Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo

Vitiligo | Tacrolimus

Egypt
Taro Pharmaceuticals USA

Completed

Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis

Atopic Dermatitis
Peking Union Medical College Hospital

Unknown

Tacrolimus Treatment for Refractory PRCA

Pure Red Cell Aplasia

China
Technical University of Munich

Completed

PEL-1235_REN-0176-I (Pelicon) (Pelicon)

Immunosuppression After Kidney Transplantation

Germany
Limerick BioPharma

Completed

Safety and Tolerability of LIM-0705 in Healthy Male Subjects (LIM)

Healthy

Australia
Panacea Biotec Ltd

Completed

Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed Condition

Healthy Volunteers

India
Panacea Biotec Ltd

Completed

Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fasting Condition

Healthy Volunteers

India
University of British Columbia
Paladin Labs Inc.

Recruiting

Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations (LCP-TAC)

Liver Transplantation | Neurotoxicity | Tremor | Tacrolimus | Immunosuppression

Canada
Philipps University Marburg Medical Center

Active, not recruiting

Viral Load Guided Immunosuppression After Lung Transplantation (VIGILung)

Transplantation Lung

Austria, Germany
Novartis
Sandoz

Completed

Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients

Renal Transplant

United States
Panacea Biotec Ltd

Completed

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed Condition

Healthy Volunteers

India
Panacea Biotec Ltd

Completed

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fasting Condition

Healthy Volunteers

India
Loyola University
Veloxis Pharmaceuticals

Recruiting

Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus

Chronic Kidney Diseases | Heart Transplant

United States
The Eye Center and The Eye Foundation for Research...

Unknown

Topical Tacrolimus in Vernal Keratoconjunctivitis

Vernal Keratoconjunctivitis

Saudi Arabia
Astellas Pharma Europe Ltd.

Terminated

A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients (PROGRESSION)

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Belgium, France, Germany, Poland, Spain, United Kingdom
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University

Unknown

Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Renal Transplant Recipients

Renal Transplantation

China
Veloxis Pharmaceuticals

Completed

Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx (LCPTacro3002)

Renal Failure

United States, Argentina, Australia, Brazil, France, Germany, Italy, Korea, Republic of, Mexico, New Zealand, Poland, Serbia, Singapore, Spain, Sweden
NURIA LLOBERAS BLANCH

Completed

OPTImization of the Dose of tacroliMUS by Bayesian Prediction (OPTIMUS)

KIDNEY TRANSPLANTATION

Spain
Chong Kun Dang Pharmaceutical

Unknown

Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients. (PK-TACT)

Kidney Transplant

Korea, Republic of
University Hospital, Limoges

Not yet recruiting

Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY) (EASY)

Liver Transplantation | Immunosuppression

France
University of California, Los Angeles
Veloxis Pharmaceuticals

Active, not recruiting

Envarsus XR® in Adolescent Renal Transplant Recipients (EnvarsusXR)

Kidney Transplantation | Renal Transplantation | Grafting, Kidney

United States
Chong Kun Dang Pharmaceutical

Unknown

Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM)

Kidney Transplant

Korea, Republic of
Astellas Pharma Korea, Inc.

Completed

A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients (SINGLE)

Kidney Transplantation | Renal Transplantation | Stable Renal Recipients

Korea, Republic of
Veloxis Pharmaceuticals

Completed

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

Renal Failure

United States
University of Cincinnati
University of Colorado, Denver; Children's Hospital Medical Center, Cincinnati

Completed

Pharmacokinetic Studies of Tacrolimus in Transplant Patients (PK)

Liver Transplant Recipients | Kidney Transplant Recipients

United States
Astellas Pharma Korea, Inc.

Completed

A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF (PeACE)

Kidney Transplantation

Korea, Republic of
Astellas Pharma Inc

Completed

A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation (MAIN)

Liver Transplantation

Korea, Republic of
Astellas Pharma Canada, Inc.

Completed

A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers

Healthy

Canada
University Hospital Tuebingen

Completed

Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial) (TAGLUMET)

Posttransplant Diabetes Mellitus

Germany
University Hospital, Tours
Astellas Pharma Inc

Unknown

Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE) (ADEQUATE)

De Novo Transplant Disease

France
Sun Yat-sen University

Completed

Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis

Nephritis, Lupus

China
University of Minnesota

Completed

Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients

Kidney Transplant Failure and Rejection

United States
University Hospital, Tours
Astellas Pharma Inc

Unknown

Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE) (ADEQUATEartère)

De Novo Transplant Disease

France
NYU Langone Health

Completed

Envarsus XR in Lung Transplant

Lung Transplant

United States
Astellas Pharma Inc

Completed

Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®

Heart Transplantation | Lung Transplantation | Pancreas (Including SPK) Transplantation

France, United Kingdom, Taiwan, Belgium, Italy, Austria
Glenmark Pharmaceuticals Ltd. India

Completed

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

Atopic Dermatitis

United States
Veloxis Pharmaceuticals
CTI Clinical Trial and Consulting Services

Completed

Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

Renal Failure

United States
University of Oslo School of Pharmacy
Oslo University Hospital

Completed

Generic Tacrolimus in the Elderly - Prograf® vs Tacni® (GenTac)

End Stage Renal Disease

Norway
Sony Tuteja
American College of Clinical Pharmacy

Completed

Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients

Kidney Transplantation

United States
Edward Geissler
Chiesi Pharmaceuticals GmbH

Recruiting

Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs (TaC:Drop)

Immunosuppression

Germany
Astellas Pharma Global Development, Inc.

Completed

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (ASTOUND)

Kidney Transplantation

United States
Edward Geissler
Excelya; Chiesi Pharmaceuticals GmbH

Active, not recruiting

Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

Prophylaxis Against Liver Transplant Rejection

Germany

3

Subscribe